Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular cholangiocarcinoma
Purpose: Investigate the performance of the LI-RADS v2017 for combined hepatocellular- cholangiocarcinoma (cHCC-CCAs) identifing the features that allow an accurate characterization
Materials and Methods: Sixty-two patients (mean age, 63 years; range, 38–80 years), with pre-surgical biopsy diagnosis of HCC, that underwent hepatic resection, comprised our retrospective study. All patients were subject to Multidetector computed tomography (MDCT), 23 to Magnetic Resonance (MR) study and 9 to contrast enhanced ultrasound (CEUS). The radiologist reported the presence of the HCC by using LIRADS v2018 assessing major and ancillary features.
Results: Final histological diagnosis was HCC for 51 patients and cHCC-CCA for 11 patients. The mean nodule size was 46.0 mm (range 10-190 mm). For cHCC-CCA the mean size was 33.5 mm (range 20-80 mm), for true HCC the mean size was 47.5 mm (range 10-190 mm). According to LIRADS categories: 54 (87.1 %) nodules as defined as LR-5, 1 (1.6%) as LR-3, and 7 (11.3 %) as LR-M. Thirty-nine nodules (63%) showed hyper-enhancement in arterial phase; among them 4 were cHCC-CCA (36.4 % of cHCC-CCA) and 35 (68.6%) true HCC. Forty-three nodules (69.3 %) showed wash-out appearance; 6 cHCC-CCAs (54.5 % of cHCC-CCA) and 37 true HCC (72.5%) had this feature. Only two cHCC-CCA patients (18.2 % of cHCC-CCA) showed capsule appearance. Five cHCC-CCA (71.4 % of cHCC-CCA) showed hyperintensity on T2-W sequences while two (28.6%) showed inhomogeneous signal in T2-W. All cHCC-CCA showed restricted diffusion. Seven cHCC-CCA patients showed a progressive contrast enhancement and satellite nodules.
Conclusion: The presence of satellite nodules, hyperintense signal on T2-W, restricted diffusion, the absence of capsule appearance in nodule that shows peripheral and progressive contrast enhancement are suggestive features of cHCC-CCA.
Copyright (c) 2020 Radiology and Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
License to Publish
Please read the terms of this agreement, print, initial page 1, sign page 3, scan and send the document as one file attached to an e-mail to firstname.lastname@example.org